跳至主要内容
临床试验/NCT05733559
NCT05733559已完成不适用

An Observational Prospective Clinical Study to Assess Clinical Performance of QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 Target in the Intended Use Population and Environment

QIAGEN Gaithersburg, Inc1 个研究点 分布在 1 个国家目标入组 565 人开始时间: 2023年2月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
565
试验地点
1
主要终点
PPA

研究概览

简要总结

This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method

详细描述

This multicentre study aims to evaluation the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Presenting with signs and symptoms of a respiratory infection.
  • Consent or assent to be obtained
  • Able to communicate (speak, read and write) in local language, and able to understand and sign the required study documents.
  • Willing and able to provide Nasopharyngeal Swab (NPS) Specimen collected per manufacturer's instructions.

排除标准

  • Subjects who, in the opinion of the Investigator, are unsuitable for participation in the study.

结局指标

主要结局

PPA

时间窗: 8 weeks

positive percentage agreement

NPA

时间窗: 8 weeks

negative percentage agreement

次要结局

未报告次要终点

研究者

发起方
QIAGEN Gaithersburg, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验